AstraZeneca

NASDAQ: AZN · Real-Time Price · USD
79.24
0.77 (0.98%)
At close: Aug 15, 2025, 3:42 PM

AstraZeneca Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 30, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
14.46B 13.59B 14.89B 13.56B 12.94B 12.68B 12.02B 11.49B 11.42B 10.88B 11.21B 10.98B 10.77B 11.39B 12.01B 9.87B 8.22B 7.32B
Cost of Revenue
2.47B 2.23B 2.73B 3.08B 2.18B 2.22B 2.31B 2.1B 1.96B 1.91B 2.9B 2.98B 3B 3.51B 4.63B 3.76B 2.19B 1.86B
Gross Profit
11.98B 11.36B 12.17B 10.48B 10.76B 10.46B 9.72B 9.4B 9.46B 8.97B 8.31B 8B 7.77B 7.88B 7.39B 6.11B 6.03B 5.46B
Operating Income
3.51B 3.67B 2.04B 2.11B 2.75B 3.12B 1.23B 1.95B 2.46B 2.55B -342M 1.25B 539M 878M -292M -1.67B 1.13B 1.9B
Interest Income
68M 84M 64M 183M 100M 111M 65M 101M 64M 78M 31M 15M 18M 17M 1M 15M 7M 20M
Pretax Income
3.13B 3.4B 1.67B 1.83B 2.4B 2.8B 897M 1.65B 2.09B 2.26B 778M 922M 247M 553M -636M -2B 764M 1.61B
Net Income
2.45B 2.92B 1.5B 1.43B 1.93B 2.18B 960M 1.37B 1.82B 1.8B 901M 1.64B 360M 386M -347M -1.65B 550M 1.56B
Selling & General & Admin
5.01B 4.57B 5.55B 5.29B 5.06B 4.63B 3.98B 4.93B 5.12B 4.19B 4.78B 4.4B 4.81B 4.96B 5.24B 2.99B 3.2B 3.03B
Research & Development
3.55B 3.16B 4.68B 3.12B 3.01B 2.78B 3.07B 2.58B 2.67B 2.61B 2.63B 2.36B 2.55B 2.13B 2.58B 2.15B 1.83B 1.71B
Other Expenses
-79M -52M -100M -25M -60M n/a n/a n/a n/a -138M -189M 949M -122M -97M -2.43B 2.3B -128M -1.18B
Operating Expenses
8.48B 7.68B 10.13B 8.38B 8.01B 7.35B 7.71B 7.44B 7B 6.67B 7.21B 6.59B 7.23B 7B 7.68B 7.44B 4.9B 3.56B
Interest Expense
439M 349M 429M 457M 443M 413M 408M 392M 431M 365M 344M 339M 311M 336M 312M 335M 326M 303M
Selling & Marketing Expenses
143M 132M 143M 145M 132M 135M 17.83B 129M 131M 134M 4.78B 126M 4.81B 4.96B 5.24B 2.99B 3.2B 3.03B
Cost & Expenses
10.95B 9.91B 12.86B 11.46B 10.19B 9.56B 10.02B 9.54B 8.96B 8.57B 10.11B 9.57B 10.23B 10.51B 12.3B 11.2B 7.09B 5.42B
Income Tax Expense
679M 481M 166M 395M 469M 620M -62M 274M 268M 458M -124M -720M -113M 165M -290M -350M 214M 46M
Shares Outstanding (Basic)
3.1B 3.1B 3.1B 3.11B 3.11B 3.1B 3.1B 3.1B 3.1B 3.1B 3.1B 3.1B 3.1B 3.1B 3.09B 2.99B 2.62B 2.62B
Shares Outstanding (Diluted)
3.12B 3.12B 3.12B 3.12B 3.12B 3.12B 3.12B 3.12B 3.12B 3.12B 3.12B 3.12B 3.12B 3.12B 3.09B 2.99B 2.64B 2.64B
EPS (Basic)
0.79 0.94 0.49 0.46 0.62 0.71 0.31 0.45 0.59 0.58 0.29 0.53 0.12 0.13 -0.11 -0.55 0.21 0.60
EPS (Diluted)
0.79 0.94 0.48 0.46 0.62 0.70 0.31 0.44 0.59 0.58 0.29 0.53 0.12 0.13 -0.11 -0.55 0.21 0.59
EBITDA
4.96B 5.08B 4.43B 4.1B 4.12B 4.57B 2.18B 3.33B 3.68B 3.89B 2.38B 2.56B 1.96B 2.2B 1.87B 1.12B 1.88B 2.71B
EBIT
3.57B 3.8B 2.1B 2.29B 2.84B 3.21B 1.3B 2.04B 2.46B 2.63B 1.12B 1.25B 539M 889M -324M -1.67B 1.09B 1.91B
Depreciation & Amortization
1.39B 1.28B 2.34B 1.82B 1.28B 1.25B 874M 1.28B 1.28B 1.5B 1.25B 1.33B 1.36B 1.31B 2.19B 2.79B 753M 797M